Combination of Hydroxychloroquine Plus Azithromycin As Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity.
Microb Drug Resist
; 27(3): 281-290, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: covidwho-1137930
ABSTRACT
The coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2, has recently emerged worldwide. In this context, there is an urgent need to identify safe and effective therapeutic strategies for treatment of such highly contagious disease. We recently reported promising results of combining hydroxychloroquine and azithromycin as an early treatment option. Although ongoing clinical trials are challenging the efficacy of this combination, many clinicians claim the authorization to or have already begun to use it to treat COVID-19 patients worldwide. The aim of this article is to share pharmacology considerations contributing to the rationale of this combination, and to provide safety information to prevent toxicity and drug-drug interactions, based on available evidence.
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Antivirales
/
Azitromicina
/
Tratamiento Farmacológico de COVID-19
/
Hidroxicloroquina
/
Antibacterianos
Tipo de estudio:
Estudio pronóstico
Límite:
Humanos
Idioma:
Inglés
Revista:
Microb Drug Resist
Asunto de la revista:
Microbiologia
/
Terapia por drogas
Año:
2021
Tipo del documento:
Artículo
País de afiliación:
Mdr.2020.0232
Similares
MEDLINE
...
LILACS
LIS